Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.

I share with you in this special investigative documentary.

Lee Kalowski Biography and Net Worth

CFO of Bicycle Therapeutics

Lee Kalowski, MBA has served as our Chief Financial Officer since July 2017 and as our President since January 2019. Prior to joining us, from September 2014 until September 2016, Mr. Kalowski served as the Chief Financial Officer and from September 2016 until May 2017, served as the consulting Chief Financial/Business Officer of Tokai Pharmaceuticals, Inc., a biopharmaceutical company. Prior to Tokai, from June 2010 to September 2014, Mr. Kalowski served in global biotechnology equity research at Credit Suisse, where he covered companies in the biopharmaceutical industry as a Senior Analyst from May 2011 until September 2014 and as an Associate from June 2010 until May 2011. Mr. Kalowski received a B.A. in biology and economics from Union College and an MBA from The Wharton School of the University of Pennsylvania. Provided by Tagnifi.

What is Lee Kalowski's net worth?: The estimated net worth of Lee Kalowski is at least $444,936.12 as of April 3rd, 2023. Mr. Kalowski owns 30,309 shares of Bicycle Therapeutics stock worth more than $444,936 as of December 21st. This net worth evaluation does not reflect any other assets that Mr. Kalowski may own. Learn More about Lee Kalowski's net worth.
How do I contact Lee Kalowski?: The corporate mailing address for Mr. Kalowski and other Bicycle Therapeutics executives is B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT. Bicycle Therapeutics can also be reached via phone at 441223261503 and via email at [email protected]. Learn More on Lee Kalowski's contact information.
Has Lee Kalowski been buying or selling shares of Bicycle Therapeutics?: Lee Kalowski has not been actively trading shares of Bicycle Therapeutics during the past quarter. Most recently, Lee Kalowski sold 376 shares of the business's stock in a transaction on Monday, April 3rd. The shares were sold at an average price of $21.11, for a transaction totalling $7,937.36. Following the completion of the sale, the chief financial officer now directly owns 30,309 shares of the company's stock, valued at $639,822.99. Learn More on Lee Kalowski's trading history.
Who are Bicycle Therapeutics' active insiders?: Bicycle Therapeutics' insider roster includes Stephen Alexander (SVP), Kate Bingham (Director), Nigel Crockett (Insider), Lee Kalowski (CFO), Nicholas Keen (Insider), Kevin Lee (CEO), and Pierre Legault (Director). Learn More on Bicycle Therapeutics' active insiders.
Are insiders buying or selling shares of Bicycle Therapeutics?: In the last twelve months, Bicycle Therapeutics insiders bought shares 2 times. They purchased a total of 1,485,397 shares worth more than $21,229,062.72. In the last twelve months, insiders at the sold shares 17 times. They sold a total of 32,657 shares worth more than $683,852.68. The most recent insider tranaction occured on December, 16th when Director Bros. Advisors Lp Baker bought 500,000 shares worth more than $7,670,000.00. Insiders at Bicycle Therapeutics own 8.5% of the company. Learn More about insider trades at Bicycle Therapeutics.
Information on this page was last updated on 12/16/2024.

Lee Kalowski Insider Trading History at Bicycle Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/3/2023	Sell	376	$21.11	$7,937.36	30,309
1/3/2023	Sell	1,815	$29.06	$52,743.90	30,685
8/27/2021	Sell	7,950	$35.15	$279,442.50	550
8/23/2021	Sell	7,500	$33.02	$247,650.00	7,500
7/29/2021	Sell	12,500	$31.51	$393,875.00	12,500
1/19/2021	Sell	15,000	$30.00	$450,000.00	15,000
12/1/2020	Sell	7,500	$22.50	$168,750.00	7,500
11/27/2020	Sell	530	$20.00	$10,600.00	530
11/25/2020	Sell	9,781	$20.07	$196,304.67	17,189
11/23/2020	Sell	17,189	$19.83	$340,857.87	17,189

Lee Kalowski Buying and Selling Activity at Bicycle Therapeutics

Bicycle Therapeutics Company Overview

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Today's Range

Now: $14.68

$14.64

$15.30

50 Day Range

MA: $21.83

$13.81

$27.51

2 Week Range

Now: $14.68

$12.17

$28.67

Volume

346,432 shs

Average Volume

404,265 shs

Market Capitalization

$1.01 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86

First JFK… next Elon?

From Porter & Company | Ad